Novo Nordisk A/S $NVO Shares Sold by Eldred Rock Partners LLC

Eldred Rock Partners LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 10.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 165,290 shares of the company’s stock after selling 18,861 shares during the quarter. Novo Nordisk A/S makes up 2.2% of Eldred Rock Partners LLC’s holdings, making the stock its 28th largest holding. Eldred Rock Partners LLC’s holdings in Novo Nordisk A/S were worth $8,410,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Martin Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after acquiring an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas boosted its stake in Novo Nordisk A/S by 105.3% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC grew its position in Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after purchasing an additional 37,453 shares in the last quarter. Markel Group Inc. grew its position in Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Novo Nordisk A/S during the 3rd quarter valued at $1,294,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 1.2%

NYSE NVO opened at $36.92 on Friday. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $164.86 billion, a PE ratio of 10.64, a price-to-earnings-growth ratio of 8.63 and a beta of 0.73. The firm’s fifty day simple moving average is $43.93 and its 200-day simple moving average is $49.98.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s payout ratio is presently 50.43%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Finally, Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.K. drug regulator NICE recommended Wegovy for heart‑disease prevention, expanding NHS access by about 1.2 million people — a material commercial win that supports longer‑term demand for Wegovy. Novo Nordisk shares rise after Wegovy recommended by Britain’s drug price regulator
• Positive Sentiment: Management launched a Wegovy subscription pricing model and expanded telehealth partnerships to lower out‑of‑pocket costs and improve adherence — a tactical move to protect market share and pricing power in self‑pay segments. NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
• Positive Sentiment: Novo released a cross‑trial comparison (ORION) showing oral Wegovy produced greater mean weight loss and fewer dropouts versus Lilly’s pill — messaging aimed at bluntly defending the oral franchise as Lilly begins commercialization. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Pipeline progress continues: Novo is advancing next‑generation metabolic candidates (including a triple‑agonist program) through early clinical trials, which supports longer‑term upside beyond current GLP‑1 competition. Novo Nordisk Triple Agonist Progress Spurs Questions On Valuation Gap
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — signaling analysts see limited near‑term upside while acknowledging the Wegovy pill momentum. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market coverage notes the shares edged higher and held up early despite Lilly’s approval — suggesting investors had partially priced in competitive pressure. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: FDA approval of Eli Lilly’s oral GLP‑1 (Foundayo/orforglipron) and an expected multi‑billion dollar commercial debut create direct pricing and market‑share pressure on Novo’s Wegovy/Ozempic franchises. Analysts and traders are pricing a more contested oral market going forward. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Broader policy/regulatory risk: reports the administration is considering tariffs of up to 100% on branded drug imports could create volatility and uncertainty for multinational drugmakers if no concessions/deals are struck. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Analyst commentary highlights intensifying duopoly dynamics with Eli Lilly, product gaps in injectables vs. Lilly, and patent/competitive lifecycle concerns — risks that could pressure growth and valuation if market share slips. Novo Nordisk: Competing In A Duopoly

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.